CERNEI, Natalia Vladimirovna, Zbynek HEGER, Jaromír GUMULEC, Ondřej ZITKA, Michal MASAŘÍK, Petr BABULA, Tomas ECKSCHLAGER, Marie STIBOROVA, Rene KIZEK and Vojtech ADAM. Sarcosine as a Potential Prostate Cancer Biomarker-A Review. International Journal of Molecular Sciences. Basel: MDPI Center, 2013, vol. 14, No 7, p. 13893-13908. ISSN 1422-0067. Available from: https://dx.doi.org/10.3390/ijms140713893.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Sarcosine as a Potential Prostate Cancer Biomarker-A Review
Authors CERNEI, Natalia Vladimirovna (498 Republic of Moldova), Zbynek HEGER (203 Czech Republic), Jaromír GUMULEC (203 Czech Republic, belonging to the institution), Ondřej ZITKA (203 Czech Republic), Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution), Petr BABULA (203 Czech Republic), Tomas ECKSCHLAGER (203 Czech Republic), Marie STIBOROVA (203 Czech Republic), Rene KIZEK (203 Czech Republic) and Vojtech ADAM (203 Czech Republic).
Edition International Journal of Molecular Sciences, Basel, MDPI Center, 2013, 1422-0067.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10600 1.6 Biological sciences
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.339
RIV identification code RIV/00216224:14110/13:00070630
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/ijms140713893
UT WoS 000322171700060
Keywords in English cancer of prostate; biomarkers; early diagnostic; prostatic specific antigen; non-invasive markers; urine; amino acids
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 19/12/2013 18:11.
Abstract
Prostate cancer (CaP) is the most common type of tumour disease in men. Early diagnosis of cancer of the prostate is very important, because the sooner the cancer is detected, the better it is treated. According to that fact, there is great interest in the finding of new markers including amino acids, proteins or nucleic acids. Prostate specific antigen (PSA) is commonly used and is the most important biomarker of CaP. This marker can only be detected in blood and its sensitivity is approximately 80%. Moreover, early stages cannot be diagnosed using this protein. Currently, there does not exist a test for diagnosis of early stages of prostate cancer. This fact motivates us to find markers sensitive to the early stages of CaP, which are easily detected in body fluids including urine. A potential is therefore attributed to the non-protein amino acid sarcosine, which is generated by glycine-N-methyltransferase in its biochemical cycle. In this review, we summarize analytical methods for quantification of sarcosine as a CaP marker. Moreover, pathways of the connection of synthesis of sarcosine and CaP development are discussed.
PrintDisplayed: 29/7/2024 22:03